Gorman Rupp Co (GRC) · Oct 23, 2026 · Earnings

Gorman-Rupp earnings beat as margins surge and debt falls

Beat — EPS $0.86 vs ~$0.70 consensus; revenue $193.3M vs ~$181.6M

Gorman-Rupp’s third-quarter earnings beat expectations, with record sales, sharply higher margins, stronger cash flow, and $58 million of debt reduction.

Gorman-Rupp is a diversified pump manufacturer serving water, wastewater, construction, agriculture, industrial, HVAC, petroleum, and fire-suppression markets, with Fill-Rite adding liquid-transfer products across agriculture and construction. The current growth story is broadening demand in construction, agriculture, and industrial applications rather than dependence on one end market.

The quarter beat on both major scorecard lines. Third-quarter EPS of $0.86 exceeded the published consensus of roughly $0.70, while revenue of $193.3 million topped roughly $181.6 million; the filing also says sales rose across all markets. The result is meaningfully ahead of what investors had been positioned for, not merely another in-line quarter.

MetricQ3 2026Q3 2025Expectation / comparison
Net sales$193.3M (Income Statement)$172.8M (Income Statement)~$181.6M published consensus
EPS$0.86 (Income Statement)$0.43 (Income Statement)~$0.70 published consensus
Gross margin33.4% (Financial Highlights)29.2% (Financial Highlights)Up 420 bps year over year
Operating margin17.5% (Financial Highlights)12.4% (Financial Highlights)Up 510 bps year over year
Adjusted EBITDA$41.8M (Financial Highlights)$32.3M (Financial Highlights)Up 29.4% year over year
Nine-month incoming orders$562.2M (Operating Update)$550.2M implied by filing comparisonUp 2.2% year over year
September 30 backlog$236.8M (Operating Update)$234.2MBelow $244.0M at December 31, 2025

Margin expansion is the most important upgrade to the business story. Gross margin reached 33.4%, and operating margin reached 17.5%, helped by volume leverage, lower LIFO expense, better medical costs, and the absence of last year’s facility-optimization charges. The improvement is therefore not entirely recurring, but the operating leverage from higher volume and better SG&A absorption appears genuine.

Cash generation is turning earnings into balance-sheet repair. Operating cash flow reached $114.9 million through nine months, while total debt fell by $58.0 million and interest expense declined. That reduces financial drag and gives the company more room to keep investing without relying on additional borrowing.

Demand is healthy but not accelerating as fast as profits. Nine-month orders rose only 2.2%, and backlog is modestly above last year but below year-end 2025. That makes the earnings beat more impressive, but it also means the company still needs continued pricing, mix, and productivity gains to sustain the current profit rate.

Bottom line: This was a genuine beat that advances Gorman-Rupp’s story from recovery toward stronger, more profitable execution. The main qualification is that order growth remains modest and part of the margin jump reflects costs that disappeared from last year’s comparison.

Original filing on SEC EDGAR

More Gorman Rupp Co news

Gorman-Rupp earnings beat as margins surge and debt falls | GRC Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.